Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials

Article ID	Journal	Published Year	Pages	File Type
8246194	International Journal of Radiation OncologyBiologyPhysics	2006	10 Pages	PDF

Abstract

Conclusion: Iodine (131I) metuximab injection is safe and active for HCC patients.

Keywords

Radioimmunotherapy HAb18G/CD147 Monoclonal antibody Clinical trial Hepatocellular carcinoma

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials

Authors

Zhi-Nan M.D., Ph.D., Li Mi, Jing M.M., Fei M.M., Qing M.M., Zheng B.S., Jin-Liang M.D., Ph.D., Hui-Jie M.D., Ph.D., Jian-Li M.D., Ph.D., Xian-Hui M.D., Ph.D., Peng PhD., Ai-Rong M.D., Ph.D., Si-He M.D., Ph.D., Ling M.D., Ph.D., Yu M.D., Ph.D.,